International News

Generic Zantac pulled after carinogien concerns

According to Bloomberg, Novartis AG’s Sandoz unit is halting worldwide distribution of generic versions of Zantac.

Ali Taghva Montreal, QC
Join the ranks of independent, free thinkers by supporting us today for as little as $1.
Support The Post Millennial

This article was published more than 1 year ago, information might not be accurate.

As the big tech tyrants tighten their grip, join us for more free speech at Parler—the anti-censorship social media platform.

Get ready to switch heartburn meds.

According to Bloomberg, Novartis AG’s Sandoz unit is halting worldwide distribution of generic versions of  Zantac.

The change occurred after regulators in Europe and the United States announced that they would be looking into a potential carcinogen being detected in the drug.

According to the FDA “Some ranitidine medicines, including some products commonly known as the brand-name drug Zantac, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels.”

NDMA is classified as a probable human carcinogen.

While Sandoz has halted distribution, the FDA is not advising users to discontinue use of ranitidine as now. If you’d like to stop as a precaution, they recommend asking for an alternative or using other OTC medicines instead.

Join and support independent free thinkers!

We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.

Support The Post Millennial